Mexico Hemorrhoids Treatment Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF MEXICO HEMORRHOIDS TREATMENT MARKET 13
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 16
2 MEXICO HEMORRHOIDS TREATMENT MARKET: SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 COUNTRY SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 DBMR TRIPOD DATA VALIDATION MODEL 21
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.6 MULTIVARIATE MODELLING 25
2.7 BY TYPE, LIFELINE CURVE 25
2.8 DBMR MARKET POSITION GRID 26
2.9 SECONDARY SOURCES 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 32
4.1 PESTEL 33
4.2 PORTER 34
5 MEXICO HEMORRHOIDS TREATMENT MARKET: REGULATORY SCENARIO 35
5.1 KEY REGULATORY INFORMATION 36
5.2 GOOD MANUFACTURING PRACTICES (GMP) INSPECTION 36
5.3 TIMELINE TO APPROVE A DRUG 37
6 SUMMARY WRITE UP (MEXICO) 38
6.1 OVERVIEW 38
7 MARKET OVERVIEW 39
7.1 DRIVERS 41
7.1.1 INCREASE IN PREVALENCE AND DIAGNOSIS OF HEMORRHOIDS 41
7.1.2 UPSURGE IN THE CASES OF CHRONIC CONSTIPATION 41
7.1.3 GROWTH IN TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HEMORRHOIDS TREATMENT 42
7.1.4 GROW IN ADOPTION OF SEDENTARY LIFESTYLE AND POOR FIBER INTAKE IN DIET 42
7.2 RESTRAINTS 43
7.2.1 HIGH COST OF TREATMENT AND CARE MANAGEMENT OF HEMORRHOIDS PATIENTS 43
7.2.2 LACK OF SKILLED WORKFORCE 43
7.3 OPPORTUNITIES 44
7.3.1 INCREASING USE OF DIETARY SUPPLEMENTS IN MEXICO 44
7.3.2 RESEARCH & DEVELOPMENT FOR NEW HERBAL TREATMENTS WITH FEWER SIDE EFFECTS. 44
7.3.3 INCREASE IN PREGNANCY RATES IN MEXICO 45
7.4 CHALLENGES 46
7.4.1 LOW HEALTHCARE FACILITIES AND AWARENESS 46
7.4.2 CHALLENGES ASSOCIATED WITH SIDE EFFECTS OF DRUGS 46
8 MEXICO HEMORRHOIDS TREATMENT MARKET, BY TYPE 47
8.1 OVERVIEW 48
8.2 EXTERNAL HEMORRHOIDS 51
8.3 INTERNAL HEMORRHOIDS 51
8.3.1 GRADE 3 52
8.3.2 GRADE 4 52
8.3.3 GRADE 2 52
8.3.4 GRADE 1 52
8.4 PROLAPSED HEMORRHOIDS 52
9 MEXICO HEMORRHOIDS TREATMENT MARKET, BY TREATMENT 53
9.1 OVERVIEW 54
9.2 MEDICATION 57
9.2.1 ANALGESICS 57
9.2.1.1 IBUPROFEN 58
9.2.1.2 ACETAMINOPHEN 58
9.2.1.3 NAPROXEN 58
9.2.1.4 ASPIRIN 58
9.2.1.5 OTHERS 58
9.2.2 STEROIDS 58
9.2.2.1 HYDROCORTISONE 59
9.2.2.2 PREDNISOLONE 59
9.2.2.3 OTHERS 59
9.2.3 ANESTHETICS 59
9.2.3.1 LIDOCAINE 59
9.2.3.2 PRAMOXINE 59
9.2.3.3 OTHERS 60

9.2.4 LAXATIVES 60
9.2.4.1 METHYLCELLULOSE 60
9.2.4.2 PSYLLIUM 60
9.2.4.3 POLYETHYLENE GLYCOL 60
9.2.4.4 OTHERS 60
9.2.5 ANTIBIOTICS 60
9.2.5.1 METRONIDAZOLE 61
9.2.5.2 DOXYCYCLINE 61
9.2.5.3 CEPHALOSPORINS 61
9.2.5.4 OTHERS 61
9.2.6 SUPPLEMENTS 61
9.2.6.1 PROBIOTICS 62
9.2.6.2 VITAMINS 62
9.2.6.3 OTHERS 62
9.2.7 OTHERS 62
9.3 SURGICAL TREATMENT 62
9.3.1 HEMORRHOID REMOVAL (HEMORRHOIDECTOMY) 63
9.3.2 HEMORRHOID STAPLING 63
9.3.3 OTHERS 63
9.4 NON-SURGICAL TREATMENT 63
9.4.1 RUBBER BAND LIGATION (RBL) 63
9.4.2 INJECTION SCLEROTHERAPY (IS) 64
9.4.3 INFRARED COAGULATION (IRC) 64
9.4.4 OTHERS 64
10 MEXICO HEMORRHOIDS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 65
10.1 OVERVIEW 66
10.2 ORAL 69
10.2.1 TABLETS 69
10.2.2 CAPSULES 69
10.2.3 OTHERS 69
10.3 TOPICAL 69
10.3.1 SUPPOSITORIES 70
10.3.2 SOOTHING CREAMS 70
10.3.3 OINTMENTS 70
10.3.4 OTHERS 70
10.4 OTHERS 71

11 MEXICO HEMORRHOIDS TREATMENT MARKET, BY DOSAGE FORM 72
11.1 OVERVIEW 73
11.2 TABLETS 76
11.2.1 NON-CHEWABLE 76
11.2.2 CHEWABLES 76
11.3 CAPSULES 76
11.4 SUPPOSITORIES 77
11.5 CREAMS 77
11.6 OINTMENTS 77
11.7 SYRUP 78
11.8 POWDER 78
11.9 OTHERS 78
12 MEXICO HEMORRHOIDS TREATMENT MARKET, BY PRODUCT TYPE 79
12.1 OVERVIEW 80
12.2 OVER-THE- COUNTER (OTC) 83
12.3 PRESCRIPTION DRUGS 83
13 MEXICO HEMORRHOIDS TREATMENT MARKET, BY AGE 84
13.1 OVERVIEW 85
13.2 ADULT 88
13.2.1 MALE 88
13.2.2 FEMALE 88
13.3 GERIATRIC 88
13.4 CHILD 89
14 MEXICO HEMORRHOIDS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 90
14.1 OVERVIEW 91
14.2 STORE BASED RETAIL 94
14.2.1 PHARMACIES AND DRUG STORES 94
14.2.2 HOSPITAL PHARMACIES 94
14.2.3 SPECIALITY STORES 94
14.2.4 CONVENIENCE STORE 94
14.2.5 SUPERMARKET/HYPERMARKET 95
14.2.6 OTHERS 95
14.3 ONLINE BASED RETAIL 95
15 MEXICO HEMORRHOIDS TREATMENT MARKET: COMPANY LANDSCAPE 96
16 SWOT ANALYSIS 97

17 COMPANY PROFILE 98
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD 98
17.1.1 COMPANY SNAPSHOT 98
17.1.2 REVENUE ANALYSIS 98
17.1.3 PRODUCT PORTFOLIO 99
17.1.4 RECENT DEVELOPMENTS 99
17.1.4.1 PARTNERSHIP 99
17.1.4.2 PRODUCT LAUNCH 99
17.2 GENOMMA LAB 100
17.2.1 COMPANY SNAPSHOT 100
17.2.2 REVENUE ANALYSIS 100
17.2.3 PRODUCT PORTFOLIO 101
17.2.4 RECENT DEVELOPMENTS 101
17.3 GLAXOSMITHKLINE PLC(2021) 102
17.3.1 COMPANY SNAPSHOT 102
17.3.2 REVENUE ANALYSIS 102
17.3.3 PRODUCT PORTFOLIO 103
17.3.4 RECENT DEVELOPMENT 103
17.4 ABBOTT 104
17.4.1 COMPANY SNAPSHOT 104
17.4.2 REVENUE ANALYSIS 105
17.4.3 PRODUCT PORTFOLIO 105
17.4.4 RECENT DEVELOPMENT 106
17.4.4.1 PRODUCT APPROVAL 106
17.5 ABBVIE INC. 107
17.5.1 COMPANY SNAPSHOT 107
17.5.2 REVENUE ANALYSIS 107
17.5.3 PRODUCT PORTFOLIO 108
17.5.4 RECENT DEVELOPMENT 108
17.5.4.1 STRATEGIC INITIATIVE 108
17.6 PERRIGO COMPANY PLC, 109
17.6.1 COMPANY SNAPSHOT 109
17.6.2 REVENUE ANALYSIS 109
17.6.3 PRODUCT PORTFOLIO 110
17.6.4 RECENT DEVELOPMENT 110
17.6.4.1 ACQUISITION 110

17.7 SANOFI 111
17.7.1 COMPANY SNAPSHOT 111
17.7.2 REVENUE ANALYSIS 111
17.7.3 PRODUCT PORTFOLIO 112
17.7.4 RECENT DEVELOPMENT 112
17.7.4.1 ACQUISITION 112
17.8 BAYER AG 113
17.8.1 COMPANY SNAPSHOT 113
17.8.2 REVENUE ANALYSIS 113
17.8.3 PRODUCT PORTFOLIO 114
17.8.4 RECENT DEVELOPMENTS 114
17.8.4.1 EVENT 114
17.8.4.2 COLLABORATION 114
17.9 CHINOIN 115
17.9.1 COMPANY SNAPSHOT 115
17.9.2 PRODUCT PORTFOLIO 115
17.9.3 RECENT DEVELOPMENT 115
17.10 FRESENIUS KABI MEXICO, SA DE CV (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 116
17.10.1 COMPANY SNAPSHOT 116
17.10.2 REVENUE ANALYSIS 116
17.10.3 PRODUCT PORTFOLIO 117
17.10.4 RECENT DEVELOPMENT 117
17.10.4.1 NEW WEBSITE LAUNCH 117
17.11 MEDTRONIC 118
17.11.1 COMPANY SNAPSHOT 118
17.11.2 REVENUE ANALYSIS 118
17.11.3 PRODUCT PORTFOLIO 119
17.11.4 RECENT DEVELOPMENT 119
17.12 NOVARTIS AG 120
17.12.1 COMPANY SNAPSHOT 120
17.12.2 REVENUE ANALYSIS 120
17.12.3 PRODUCT PORTFOLIO 121
17.12.4 RECENT DEVELOPMENT 121
17.13 PFIZER INC. 122
17.13.1 COMPANY SNAPSHOT 122
17.13.2 REVENUE ANALYSIS 122
17.13.3 PRODUCT PORTFOLIO 123
17.13.4 RECENT DEVELOPMENTS 123
17.13.4.1 MERGER 123
17.13.4.2 STRATEGIC INITIATIVES 123
17.14 PROCTER & GAMBLE 124
17.14.1 COMPANY SNAPSHOT 124
17.14.2 REVENUE ANALYSIS 124
17.14.3 PRODUCT PORTFOLIO 125
17.14.4 RECENT DEVELOPMENT 125
17.14.4.1 PRODUCT LAUNCH 125
18 QUESTIONNAIRE 126
19 RELATED REPORTS 130